Determining optimum dose and acute tolerance of triazolam.
The present two-phase study was designed to determine the optimum hynotic dose of triazolam and to assess any evidence of acute tolerance. Subjective and objective data were used to assess hypnotic efficacy. In the dose-titration phase, the dose of triazolam was increased in 0-5 mg increments to the highest level tolerated by each individual patient. Maximum tolerable doses ranged between 0-5 and 3-0 mg; however, all subjects experienced maximum therapeutic effect at 1-5 mg triazolam. During the 4-night acute tolerance portion of the study no clear evidence of tolerance was found.
D000328:Adult; D014151:Anti-Anxiety Agents / Q000008:administration & dosage*; D001259:Ataxia / Q000139:chemically induced; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004361:Drug Tolerance; D006801:Humans; D008297:Male; D008606:Mental Processes / Q000187:drug effects; D008875:Middle Aged; D012893:Sleep Wake Disorders / Q000188:drug therapy*; D014229:Triazolam / Q000008:administration & dosage* / Q000627:therapeutic use
D014151:Anti-Anxiety Agents; D014229:Triazolam